GHK-Cu: Copper Peptide Tissue Repair and Anti-Ageing Research

GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II), or copper peptide GHK) is an endogenous tripeptide-copper(II) complex first isolated from human plasma albumin by Loren Pickart in 1973. It is found naturally in plasma, urine, and saliva, and its concentration declines significantly with age — from approximately 200 ng/mL at age 20 to under 80 ng/mL by age 60 — making it a focus of anti-ageing and tissue repair research.

Biochemistry and Copper Coordination

The GHK tripeptide (Gly-His-Lys) binds copper(II) ions via its histidine imidazole group and N-terminal amine in a stable 1:1 complex. This copper chelation is functionally important: copper is an essential cofactor for multiple enzymes critical to tissue remodelling, including lysyl oxidase (collagen and elastin crosslinking), copper-zinc superoxide dismutase (antioxidant defence), and ceruloplasmin. GHK-Cu acts as a copper transport and delivery system, facilitating copper bioavailability in tissue microenvironments.

Wound Healing and Tissue Repair

Pickart's original observations established that GHK-Cu promoted wound healing in tissue culture models. Subsequent animal and human research has characterised the mechanisms:

• Collagen synthesis: GHK-Cu stimulates type I and type III collagen production in fibroblasts via TGF-β pathway activation. Kjaer et al. and others demonstrated increased collagen in aged skin with topical application.
• Glycosaminoglycan synthesis: Increased decorin, chondroitin sulphate, and hyaluronic acid production has been documented, supporting extracellular matrix quality.
• Anti-proteolytic effects: GHK-Cu inhibits MMP-1 (collagenase) and MMP-2/9 (gelatinases), reducing collagen degradation while stimulating TIMP expression.
• Angiogenesis: VEGF upregulation in wound beds promotes new vessel formation, improving tissue perfusion during repair.

Gene Expression Research

Microarray studies by Pickart and Margolina (2009, 2012) demonstrated that GHK modulates expression of over 4,000 human genes. Notably, it upregulates genes associated with DNA repair, antioxidant defence, and anti-inflammatory signalling, while downregulating genes associated with oncogenic signalling (particularly TGF-β1-mediated pro-fibrotic and pro-cancer pathways). This broad gene expression modulation — described as a "system reboot" toward a more youthful gene expression pattern — is a major focus of longevity research.

In particular, GHK upregulates VEGF, EGF, FGF, PDGF family members relevant to tissue repair, while simultaneously downregulating inflammatory mediators including TNF-α signalling components.

Anti-Ageing and Skin Research

GHK-Cu is among the most studied peptides in cosmetic dermatology research. Double-blind trials with topical GHK-Cu formulations have demonstrated improvements in skin thickness, laxity, and fine line reduction in aged skin. Leyden et al. (2011) and other investigators published controlled data showing improvements in several objective skin quality metrics versus vehicle control.

The mechanism combines multiple complementary effects: restored collagen structure, improved glycosaminoglycan matrix, reduced oxidative damage via copper-SOD activity, and reduced inflammatory signalling. The age-related decline in plasma GHK provides a rationale for investigating exogenous supplementation in ageing tissue.

Systemic Anti-Inflammatory Research

Beyond dermal applications, GHK-Cu has been studied in lung injury and systemic inflammation models. It demonstrates anti-inflammatory effects via suppression of NF-κB target gene expression and cytokine production. Research in COPD and lung injury models shows GHK reduces inflammatory gene expression profiles associated with pulmonary damage, opening potential applications in respiratory research.